title: Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial.
authors.forename: Silvia
authors.initials: S
authors.lastname: Govi
authors.forename: Giuseppina P
authors.initials: GP
authors.lastname: Dognini
authors.forename: Giada
authors.initials: G
authors.lastname: Licata
authors.forename: Roberto
authors.initials: R
authors.lastname: Crocchiolo
authors.forename: Antonio Giordano
authors.initials: AG
authors.lastname: Resti
authors.forename: Maurilio
authors.initials: M
authors.lastname: Ponzoni
authors.forename: Andrés J M
authors.initials: AJ
authors.lastname: Ferreri
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use*; D003230:Conjunctival Neoplasms / Q000188:drug therapy; D005134:Eye Neoplasms / Q000188:drug therapy*; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D017291:Clarithromycin